3-(1H-imidazol-2-ylmethyl)pyridine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-(1H-imidazol-2-ylmethyl)pyridine
• 化学式: C₉H₉N₃
• 分子量: 159.191
• InChiKey: SMWGXGDAMQMEFH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(1H-imidazol-2-ylmethyl)pyridine 、 碘甲烷 在 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 0.58h， 以42%的产率得到3-[(1-methyl-1H-imidazol-2-yl)methyl]pyridine
  参考文献：
  名称：

  Homoazanicotine:  A Structure-Affinity Study for Nicotinic Acetylcholine (nACh) Receptor Binding

  摘要：

  We have recently identified 3-[(1-methyl)-4,5-dihydro-1H-imidazol-2-yl)methyl]pyridine (homo-azanicotine, 8) as a novel nicotinic acetylcholinergic (nACh) receptor ligand. In the present investigation, after we determined that 8 binds selectively at nicotinic (K-i = 7.8 nM) vs muscarinic (K-i > 10 000 nM) acetylcholinergic receptors, we examined its structure-affinity relationships for nACh receptor binding. The features investigated included the influence of (i) the composition of connector that separates the two rings, (ii) the N-methyl group, (iii) the ring opening of the imidazoline ring, (iv) the pyridine nitrogen atom, and (v) the aromatization of the imidazoline ring on nACh receptor affinity. As with nicotine, the parent structure seems optimal and most structural changes reduce nACh receptor affinity. Also, as with nicotine analogues, alteration of the spacer group influences affinity in a manner that is somewhat different than that seen with the parent structure.

  DOI：

  10.1021/jm020188s
• 作为产物：
  描述：

  3-吡啶乙腈 在 sodium methylate 作用下， 以 甲醇 为溶剂， 反应 45.0h， 生成 3-(1H-imidazol-2-ylmethyl)pyridine
  参考文献：
  名称：

  Homoazanicotine:  A Structure-Affinity Study for Nicotinic Acetylcholine (nACh) Receptor Binding

  摘要：

  We have recently identified 3-[(1-methyl)-4,5-dihydro-1H-imidazol-2-yl)methyl]pyridine (homo-azanicotine, 8) as a novel nicotinic acetylcholinergic (nACh) receptor ligand. In the present investigation, after we determined that 8 binds selectively at nicotinic (K-i = 7.8 nM) vs muscarinic (K-i > 10 000 nM) acetylcholinergic receptors, we examined its structure-affinity relationships for nACh receptor binding. The features investigated included the influence of (i) the composition of connector that separates the two rings, (ii) the N-methyl group, (iii) the ring opening of the imidazoline ring, (iv) the pyridine nitrogen atom, and (v) the aromatization of the imidazoline ring on nACh receptor affinity. As with nicotine, the parent structure seems optimal and most structural changes reduce nACh receptor affinity. Also, as with nicotine analogues, alteration of the spacer group influences affinity in a manner that is somewhat different than that seen with the parent structure.

  DOI：

  10.1021/jm020188s

文献信息

• [EN] 5-AMINOINDENO(1,2-C)PYRAZOL-4-ONES AS ANTI-CANCER AND ANTI-PROLIFERATIVE AGENTS<br/>[FR] 5-AMINOINDENO(1,2-C)-PYRAZOL-4-ONES AGENTS ANTICANCEREUX ET ANTIPROLIFERATIFS
  申请人：DU PONT PHARMACEUTICALS COMPANY

  公开号：WO1999054308A1

  公开（公告）日：1999-10-28

  (EN) The present invention relates to the synthesis of a new class of indeno [1,2-c]pyrazol-4-ones of formula (I), that are potent inhibitors of the class of enzymes known as cyclin dependent kinases, which relate to the catalytic subunits cdk1-7 and their regulatory subunits known as cyclines A-G. This invention also provides a novel method of treating cancer or other proliferative diseases by administering a therapeutically effective amount of one of these compounds or a pharmaceutically acceptable salt form thereof. Alternatively, one can treat cancer or other proliferative diseases by administering a therapeutically effective combination of one of the compounds of the present invention and one or more other known anti-cancer or anti-proliferative agents.(FR) L'invention porte sur la synthèse d'une nouvelle classe d'indéno(1,2-c)-pyrazol-4-ones de formule (I) s'avérant de puissants inhibiteurs d'enzymes dites kinases à dépendance cycline se rapportant aux sous-unités catalytiques cdk1-7 et à leurs sous-unités régulatrices dites cyclines A-G. L'invention porte également sur un nouveau procédé de traitement du cancer et autres maladies proliférantes par administration de doses à effet thérapeutique de ces composés ou de leurs sels pharmacocompatibles. On peut par ailleurs traiter le cancer et d'autres maladies proliférantes par administration d'une combinaison à effet thérapeutique de l'un des composés de l'invention et d'un ou plusieurs agents anticancéreux ou antiprolifératifs connus.

  本发明涉及合成一种新的indeno [1,2-c] pyrazol-4-ones类化合物，其化学式为(I)，这些化合物是cyclin dependent kinases酶类的有效抑制剂，与催化亚单位cdk1-7及其调节亚单位cyclines A-G有关。本发明还提供了一种治疗癌症或其他增生性疾病的新方法，即通过给予这些化合物或其药学上可接受的盐形式的治疗有效剂量。另外，可以通过给予本发明化合物之一和一个或多个其他已知的抗癌或抗增生药物的治疗有效组合来治疗癌症或其他增生性疾病。
• CURABLE COMPOSITION
  申请人：LG Chem, Ltd.

  公开号：EP2977406A1

  公开（公告）日：2016-01-27

  The present invention relates to a curable composition and an adhesive film including the same, and provides a curable composition and an adhesive film which may prevent damage to an element from moisture contained in the composition, ionic substances, and other foreign substances, and effectively block electrochemical corrosion, thereby improving a lifespan and durability of an organic electronic device.

  本发明涉及一种可固化组合物和包括其在内的胶膜，并提供了一种可固化组合物和胶膜，可防止组合物中所含水分、离子物质和其他外来物质对元件造成损害，并有效阻止电化学腐蚀，从而提高有机电子设备的寿命和耐用性。
• Curable composition
  申请人：LG CHEM, LTD.

  公开号：US10457842B2

  公开（公告）日：2019-10-29

  The present invention relates to a curable composition and an adhesive film including the same, and provides a curable composition and an adhesive film which may prevent damage to an element from moisture contained in the composition, ionic substances, and other foreign substances, and effectively block electrochemical corrosion, thereby improving a lifespan and durability of an organic electronic device.

  本发明涉及一种可固化组合物和包括其在内的胶膜，并提供了一种可固化组合物和胶膜，可防止组合物中所含水分、离子物质和其他外来物质对元件造成损害，并有效阻止电化学腐蚀，从而提高有机电子设备的寿命和耐用性。
• 5-AMINOINDENO(1,2-C)PYRAZOL-4-ONES AS ANTI-CANCER AND ANTI-PROLIFERATIVE AGENTS
  申请人：Du Pont Pharmaceuticals Company

  公开号：EP1071668A1

  公开（公告）日：2001-01-31
• ACYLSEMICARBAZIDES AS CYCLIN DEPENDENT KINASE INHIBITORS USEFUL AS ANTI-CANCER AND ANTI-PROLIFERATIVE AGENTS
  申请人：Bristol-Myers Squibb Pharma Company

  公开号：EP1417177A2

  公开（公告）日：2004-05-12